Citius Oncology, Inc. financial data

Symbol
CTOR on Nasdaq
Location
11 Commerce Drive, 1 St Floor, Cranford, NJ
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2025 - Aug 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 36 % +31.7%
Quick Ratio 30.9 %
Debt-to-equity 130 %
Return On Equity -68.4 % -2.66%
Return On Assets -29.7 % -14.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 78.4M shares +3227%
Common Stock, Shares, Outstanding 71.6M shares +2956%
Entity Public Float 47.7T USD
Common Stock, Value, Issued 7.16K USD +4184%
Weighted Average Number of Shares Outstanding, Basic 71.6M shares +6%
Weighted Average Number of Shares Outstanding, Diluted 71.6M shares +6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 6.64M USD -17.1%
General and Administrative Expense 11.2M USD +129%
Operating Income (Loss) -4.94M USD -6.83%
Nonoperating Income (Expense) 3.25M USD -22%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -25.6M USD -10.3%
Income Tax Expense (Benefit) 937K USD +83.5%
Net Income (Loss) Attributable to Parent -26.6M USD -87.5%
Earnings Per Share, Basic 0 USD/shares -100%
Earnings Per Share, Diluted 0 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 112 USD
Inventory, Net 17.2M USD
Assets, Current 18.3M USD +44569%
Assets 91.7M USD +86.4%
Accounts Payable, Current 8.67M USD
Accrued Liabilities, Current 8.46M USD +1641%
Liabilities, Current 53M USD +1620%
Deferred Income Tax Liabilities, Net 2.52M USD
Liabilities 59.3M USD
Retained Earnings (Accumulated Deficit) -59M USD -1842%
Stockholders' Equity Attributable to Parent 32.4M USD +90.2%
Liabilities and Equity 91.7M USD +86.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -192K USD -13.6%
Net Cash Provided by (Used in) Financing Activities -24.5M USD
Net Cash Provided by (Used in) Investing Activities 24.7M USD
Common Stock, Shares Authorized 400M shares +167%
Common Stock, Shares, Issued 71.6M shares +2956%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 584 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 112 USD
Deferred Tax Assets, Valuation Allowance 4.93M USD +21.9%
Deferred Income Tax Expense (Benefit) 264K USD +83.5%
Deferred Tax Assets, Operating Loss Carryforwards 7.53M USD +62.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +900%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 91.4M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 7.69M USD +8.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%